BRPI1007173A2 - composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico - Google Patents

composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico

Info

Publication number: BRPI1007173A2
Authority: BR; Brazil
Prior art keywords: neuropharmaceutical; sorbic; mitigating; symptoms; derivatives
Prior art date: 2009-01-20

Application number

BRPI1007173A

Other languages

English (en)

Inventor

Guochuan Emil Tsai

Original Assignee

Los Angeles Biomed Res Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-20

Filing date

2010-01-19

Publication date

2016-02-23

2010-01-19 Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst

2016-02-23 Publication of BRPI1007173A2 publication Critical patent/BRPI1007173A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Botany (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1007173A 2009-01-20 2010-01-19 composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico BRPI1007173A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14593109P	2009-01-20	2009-01-20
PCT/US2010/021420 WO2010085452A1 (en)	2009-01-20	2010-01-19	Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Publications (1)

Publication Number	Publication Date
BRPI1007173A2 true BRPI1007173A2 (pt)	2016-02-23

Family

ID=42354348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007173A BRPI1007173A2 (pt)	2009-01-20	2010-01-19	composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico

Country Status (12)

Country	Link
US (5)	US9649304B2 (pt)
EP (3)	EP2389187B1 (pt)
JP (1)	JP5675650B2 (pt)
CN (1)	CN102292094B (pt)
AU (1)	AU2010206886B2 (pt)
BR (1)	BRPI1007173A2 (pt)
CA (2)	CA3037010A1 (pt)
DK (2)	DK2389187T3 (pt)
ES (2)	ES2615884T3 (pt)
HR (2)	HRP20170089T1 (pt)
MX (3)	MX353752B (pt)
WO (1)	WO2010085452A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3037010A1 (en)	2009-01-20	2010-07-29	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente	Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
WO2011017319A1 (en) *	2009-08-03	2011-02-10	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods of treating disorders associated with protein polymerization
US8809617B2 (en)	2009-11-05	2014-08-19	The University of Pittsburgh—Of the Commonwealth System of Higher Education	Automated high-content live animal drug screening using C. elegans
US9072772B2 (en)	2009-11-05	2015-07-07	University of Pittsburgh—of the Commonwealth System of Higher Education	Methods of treating disorders associated with protein aggregation
JP5751109B2 (ja) *	2011-09-20	2015-07-22	ニプロ株式会社	生体試料中の馬尿酸およびメチル馬尿酸のそれぞれの濃度を測定する方法
US9517254B2 (en) *	2012-08-06	2016-12-13	S1 Biopharma, Inc.	Treatment regimens
US9265458B2 (en)	2012-12-04	2016-02-23	Sync-Think, Inc.	Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en)	2013-03-11	2016-07-05	Sync-Think, Inc.	Optical neuroinformatics
WO2014168727A1 (en) *	2013-03-15	2014-10-16	Shire Llc	Fixed dose combination treatment for schizophrenia
DE212014000063U1 (de) *	2014-03-24	2015-10-12	China Medical University	Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung
EP3335126A4 (en)	2015-08-11	2019-05-01	Cognoa, Inc.	METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY
US11972336B2 (en)	2015-12-18	2024-04-30	Cognoa, Inc.	Machine learning platform and system for data analysis
US10653639B2 (en)	2016-05-16	2020-05-19	Cv Sciences, Inc.	Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
DK3468944T3 (da) *	2016-06-13	2023-02-06	Syneurx Int Taiwan Corp	Co-krystaller af natriumbenzoat og anvendelser deraf
WO2017215591A1 (en) *	2016-06-13	2017-12-21	Syneurx International (Taiwan) Corp.	Use of lithium benzoate for treating central nervous system disorders
RU2765625C2 (ru)	2016-06-13	2022-02-01	Сайньюрекс Интернэшнл (Тайвань) Корп.	Сокристаллы бензоата лития и их применения
BR112019005542A2 (pt) *	2016-09-23	2019-06-18	Delpor Inc	composições para compostos de agente terapêutico de pequenas moléculas
US11369579B2 (en)	2016-10-24	2022-06-28	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) *	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
EP3539033B1 (en)	2016-11-14	2024-10-02	Cognoa, Inc.	Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
TW202345829A (zh) *	2016-12-02	2023-12-01	美商紐羅克里生物科學有限公司	戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
MX382195B (es)	2016-12-20	2025-03-13	Lts Lohmann Therapie Systeme Ag	Sistema terapeutico transdermico que contiene asenapina
CN110087641B (zh)	2016-12-20	2024-03-12	罗曼治疗系统股份公司	含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
AU2018219846A1 (en)	2017-02-09	2019-09-12	Cognoa, Inc.	Platform and system for digital personalized medicine
TWI626043B (zh) *	2017-06-13	2018-06-11	心悅生醫股份有限公司	苯甲酸鋰用於治療中樞神經系統疾病的用途
CN110799180A (zh)	2017-06-26	2020-02-14	罗曼治疗系统股份公司	含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
JP6550426B2 (ja) *	2017-07-26	2019-07-24	カオシュン・チャン・グン・メモリアル・ホスピタル	認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AU2017435893B2 (en)	2017-10-10	2023-06-29	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
US10098861B1 (en)	2017-10-24	2018-10-16	Syneurx International (Taiwan) Corp.	Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
KR20200088861A (ko) *	2017-11-22	2020-07-23	치에-신 린	우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체
CN112236138B (zh)	2017-12-05	2024-05-31	赛诺维信制药公司	晶体形式及其制备方法
EP3720434A4 (en)	2017-12-05	2021-09-01	Sunovion Pharmaceuticals Inc.	NON-RACEMIC MIXTURES AND THEIR USE
PL3810100T3 (pl)	2018-06-20	2025-05-12	Lts Lohmann Therapie-Systeme Ag	Transdermalny system terapeutyczny zawierający asenapinę
US12329862B2 (en)	2018-06-20	2025-06-17	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system containing asenapine
KR102051624B1 (ko) *	2018-11-30	2019-12-02	아밀로이드솔루션 주식회사	트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물
KR102785528B1 (ko)	2019-03-22	2025-03-21	코그노아, 인크.	개인 맞춤식 디지털 치료 방법 및 디바이스
US12433904B2 (en)	2019-04-17	2025-10-07	Compass Pathfinder Limited	Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
PH12021553056A1 (en)	2019-06-04	2023-09-11	Sunovion Pharmaceuticals Inc	Modified release formulations and uses thereof
CN119949562A (zh) *	2020-03-27	2025-05-09	深圳市合瑞生物科技有限公司	组合物及其制品
CA3180941C (en) *	2020-06-01	2024-01-02	Rajaram Samant	Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
US20240374544A1 (en) *	2021-08-30	2024-11-14	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
EP4447952A4 (en) *	2021-12-16	2025-11-19	Us Gov Veterans Affairs	Benzoic acid salts for the treatment of injuries and disorders of the nervous system
US20240120050A1 (en) *	2022-10-07	2024-04-11	Insight Direct Usa, Inc.	Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3498989A (en)	1969-04-16	1970-03-03	American Home Prod	Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en)	1972-03-09	1975-03-11	Nikolaus R Hansl	Substituted amino ethyl meta benzoic acid esters
US4041174A (en) *	1974-08-16	1977-08-09	Rom-Amer Pharmaceuticals, Ltd.	Method of treating depression
US5204356A (en)	1985-07-24	1993-04-20	Glaxo Group Limited	Treatment of anxiety
US6150354A (en)	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) *	1988-08-16	1988-09-21	Ucb Sa	Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) *	1991-02-22	2004-06-08	Howard K. Shapiro	Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
FR2700117B1 (fr)	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) *	1993-11-26	1995-06-01	Karla Dr Lehmann	Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) *	1994-07-11	1995-09-26	Janssen Pharmaceutica N.V.	Risperidone oral formulation
WO2001041707A2 (en) *	1999-12-08	2001-06-14	Vanderbilt University	Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20040156872A1 (en) *	2000-05-18	2004-08-12	Elan Pharma International Ltd.	Novel nimesulide compositions
EA005621B1 (ru)	2000-07-21	2005-04-28	Х.Лундбекк А/С	Гетероциклические соединения в качестве ингибиторов транспортера глицина
ES2310410T3 (es)	2000-08-14	2009-01-01	Teva Pharmaceutical Industries Ltd.	Preparacion de risperidona.
US20030185754A1 (en) *	2001-01-16	2003-10-02	Genset, S.A.	Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
EA006654B1 (ru) *	2001-01-16	2006-02-24	Женсет С. А.	Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
US20030162825A1 (en) *	2001-11-09	2003-08-28	Sepracor Inc.	D-amino acid oxidase inhibitors for learning and memory
WO2003047558A2 (en)	2001-12-03	2003-06-12	Genset S.A.	Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20070053976A1 (en) *	2002-05-17	2007-03-08	Eisai R & D Management Co., Ltd.	Novel combination of drugs as antidepressant
US7053122B2 (en)	2002-08-09	2006-05-30	Pfizer Inc	Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) *	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004037234A2 (en) *	2002-10-24	2004-05-06	Merz Pharma Gmbh & Co. Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004065348A1 (en) *	2003-01-23	2004-08-05	Pfizer Products Inc.	Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
US20050004104A1 (en) *	2003-05-30	2005-01-06	Cali Brian M.	Methods for the protection of memory and cognition
JP2006526635A (ja) *	2003-06-02	2006-11-24	サマリタン，ファーマスーティカルス，インク．	血清中コルチゾール量を調節する方法および組成物
CA2552098A1 (en)	2003-12-29	2005-07-21	Sepracor Inc.	Benzo[d]isoxazol-3-ol daao inhibitors
ATE504588T1 (de)	2004-01-27	2011-04-15	Synthon Bv	Stabile salze von olanzapin
WO2005079851A2 (en) *	2004-02-18	2005-09-01	Sepracor, Inc.	Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005094514A2 (en)	2004-03-24	2005-10-13	Merck & Co., Inc.	Heteroaryl piperidine glycine transporter inhibitors
CA2565159A1 (en) *	2004-05-06	2005-12-15	Cydex, Inc.	Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
WO2006096439A2 (en)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006129160A2 (en) *	2005-06-01	2006-12-07	Aurobindo Pharma Limited	Stable aqueous oral solution of risperidone
US20110045065A1 (en)	2005-07-11	2011-02-24	Ashok Vasantray Vyas	Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en)	2005-11-14	2010-10-12	Barr Laboratories, Inc.	Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US20100048713A1 (en) *	2006-01-06	2010-02-25	Aarhus Universitet	Compounds acting on the serotonin transporter
GB0603181D0 (en) *	2006-02-17	2006-03-29	Merck Sharp & Dohme	Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) *	2006-08-09	2008-02-21	Pfizer Inc.	Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080070984A1 (en)	2006-09-15	2008-03-20	Tran Pierre V	Compositions and Methods of Treating Schizophrenia
CA3037010A1 (en)	2009-01-20	2010-07-29	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente	Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

2010
- 2010-01-19 CA CA3037010A patent/CA3037010A1/en active Pending
- 2010-01-19 EP EP10733788.3A patent/EP2389187B1/en active Active
- 2010-01-19 US US12/689,957 patent/US9649304B2/en not_active Expired - Fee Related
- 2010-01-19 WO PCT/US2010/021420 patent/WO2010085452A1/en not_active Ceased
- 2010-01-19 ES ES10733788.3T patent/ES2615884T3/es active Active
- 2010-01-19 EP EP15192644.1A patent/EP3006024B1/en active Active
- 2010-01-19 CA CA2750028A patent/CA2750028C/en active Active
- 2010-01-19 JP JP2011546429A patent/JP5675650B2/ja not_active Expired - Fee Related
- 2010-01-19 CN CN2010800050053A patent/CN102292094B/zh not_active Expired - Fee Related
- 2010-01-19 EP EP15192647.4A patent/EP3006023B1/en active Active
- 2010-01-19 MX MX2011007712A patent/MX353752B/es active IP Right Grant
- 2010-01-19 MX MX2017002152A patent/MX380715B/es unknown
- 2010-01-19 DK DK10733788.3T patent/DK2389187T3/en active
- 2010-01-19 DK DK15192644.1T patent/DK3006024T3/da active
- 2010-01-19 AU AU2010206886A patent/AU2010206886B2/en not_active Ceased
- 2010-01-19 MX MX2017002151A patent/MX374638B/es unknown
- 2010-01-19 ES ES15192644T patent/ES2731228T3/es active Active
- 2010-01-19 BR BRPI1007173A patent/BRPI1007173A2/pt not_active IP Right Cessation
- 2010-01-19 HR HRP20170089TT patent/HRP20170089T1/hr unknown
2014
- 2014-11-24 US US14/552,298 patent/US9675604B2/en active Active
2017
- 2017-01-19 US US15/409,655 patent/US10039730B2/en active Active
- 2017-01-19 US US15/409,775 patent/US10149845B2/en active Active
2018
- 2018-11-21 US US16/197,674 patent/US11529342B2/en active Active
2019
- 2019-05-21 HR HRP20190933TT patent/HRP20190933T1/hr unknown

Also Published As

Publication number	Publication date
CN102292094B (zh)	2013-08-14
CN102292094A (zh)	2011-12-21
DK3006024T3 (da)	2019-06-03
US9675604B2 (en)	2017-06-13
US10039730B2 (en)	2018-08-07
JP2012515720A (ja)	2012-07-12
US9649304B2 (en)	2017-05-16
CA3037010A1 (en)	2010-07-29
EP2389187A1 (en)	2011-11-30
MX380715B (es)	2025-03-12
ES2731228T3 (es)	2019-11-14
HRP20190933T1 (hr)	2019-07-26
EP3006024B1 (en)	2019-03-20
EP3006024A1 (en)	2016-04-13
JP5675650B2 (ja)	2015-02-25
US11529342B2 (en)	2022-12-20
US20100189818A1 (en)	2010-07-29
US20170189358A1 (en)	2017-07-06
EP2389187A4 (en)	2013-12-04
MX2011007712A (es)	2011-12-14
EP3006023A1 (en)	2016-04-13
WO2010085452A9 (en)	2011-01-06
CA2750028A1 (en)	2010-07-29
WO2010085452A1 (en)	2010-07-29
AU2010206886A1 (en)	2011-09-08
US10149845B2 (en)	2018-12-11
MX353752B (es)	2018-01-26
EP3006023B1 (en)	2019-06-26
DK2389187T3 (en)	2017-02-20
EP2389187B1 (en)	2016-11-16
ES2615884T3 (es)	2017-06-08
US20150099015A1 (en)	2015-04-09
AU2010206886B2 (en)	2016-05-05
CA2750028C (en)	2019-05-07
US20170181989A1 (en)	2017-06-29
MX374638B (es)	2025-03-06
US20190151301A1 (en)	2019-05-23
HRP20170089T1 (hr)	2017-03-24

Publication	Publication Date	Title
BRPI1007173A2 (pt)	2016-02-23	composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico
BRPI0915273A2 (pt)	2015-08-04	Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém.
CL2013001339A1 (es)	2014-03-07	Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
BR112012001915A2 (pt)	2016-11-08	derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso.
BR112012018695A2 (pt)	2016-04-12	compostos pirazol como antagonistas crth2
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0922435A2 (pt)	2018-09-11	"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
CL2014002589A1 (es)	2015-01-30	Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BR112012028707A2 (pt)	2019-09-24	composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
BRPI0918841A2 (pt)	2015-12-08	derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
EP2799543A4 (en)	2015-07-29	HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
BR112015003376A2 (pt)	2017-07-04	composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2012000620A1 (es)	2013-09-06	Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
BRPI1008878A2 (pt)	2019-09-24	compostos heterocíclicos, composições farmacêuticas contendo os mesmos, e seus usos como inibidores de transportador de glicina 1
BRPI0915897A2 (pt)	2015-11-03	compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BR112014014769A2 (pt)	2017-06-13	Composto, composição farmacêutica, e, uso de um composto ou sal.
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
CL2014000849A1 (es)	2014-08-29	Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BRPI0717369A2 (pt)	2014-10-07	Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0916571A2 (pt)	2015-11-10	composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0907228A2 (pt)	2015-07-14	Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Legal Events

Date	Code	Title	Description
2016-03-01	B15I	Others concerning applications: loss of priority
2016-03-29	B151	Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]	Free format text: FOI ANULADO O DESPACHO 15.9 PUBLICADO NA RPI 2356 DE 01/03/2016 POR TER SIDO INDEVIDA.
2017-12-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-06-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-06-26	B07B	Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
2020-05-05	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-07-14	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-12-08	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-02-17	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2024-11-12	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 15A ANUIDADE.
2025-03-06	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2810 DE 12-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.